NEW YORK, NY / ACCESSWIRE / July 5, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...

Erik Kinnmann became the CEO of NeuroVive Pharmaceutical AB (STO:NVP) in 2016. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, ...

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: "NeuroVive is right in a really interesting development phase, and I look forward to using my experience of similar positions to help move the company ...

Erik Kinnmann has been the CEO of NeuroVive Pharmaceutical AB (STO:NVP) since 2016. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider ...

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, presents preclinical data from a new generation of sanglifehrin-based compounds with potent ...

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: "He will provide expertise and focus across the organization and establish solid partnerships that will enhance our R&D program further. His broad ...

NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company, has signed a collaboration agreement with Isomerase Therapeutics to develop the molecules that were recently acquired from ...

NeuroVive reported a breakthrough for the NVP025 project for mitochondrial myopathies. The Board of Directors of NeuroVive has resolved, subject to approval by the Extraordinary General Meeting, to ...

LUND, Sweden, March 7, 2019 /PRNewswire/ --NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company has successfully conducted a directed new issue of shares ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with ...

LUND, Sweden, March 19, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the first healthy volunteer in the company's KL1333 phase Ia/b study ...